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The Minimal Clinically Important Difference for the Rasch Neuropsychiatric Inventory 1 
Irritability and Aggression Scale for Traumatic Brain Injury 2 
Abstract 3 
Objective: To determine the Minimal Clinically Important Difference (MCID) for a 4 
Rasch measure derived from the Irritability/Lability and Agitation/Aggression subscales of the 5 
Neuropsychiatric Inventory (NPI-TBI-IA) Design:  Distribution-based statistical methods were 6 
applied to retrospective data to determine candidates for the MCID.  These candidates were 7 
evaluated by anchoring the NPI-TBI-IA to Global Impression of Change (GIC) ratings by 8 
participants, significant others, and a supervising physician.  Main Outcome Measure: NPI-9 
TBI-IA. Setting:  Postacute rehabilitation outpatient clinic.  Participants:  274 cases with 10 
observer ratings;  232 cases with self-ratings by participants with moderate-severe TBI at least 6 11 
months post-injury. Results: For observer ratings on the NPI-TBI-IA, anchored comparisons 12 
found an improvement of ½ SD was associated with at least minimal general improvement on 13 
GIC by a significant majority (69-80%); ½ SD improvement on participant NPI-TBI-IA self-14 
ratings was also associated with at least minimal improvement on the GIC by a substantial 15 
majority (77-83%).  The percent indicating significant global improvement did not increase 16 
markedly on most ratings at higher levels of improvement on the NPI-TBI-IA.  Conclusions:  A 17 
½ SD improvement on the NPI-TBI-IA indicates the MCID for both observer and participant 18 
ratings on this measure.   19 
Abbreviations 20 
GIC  Global Impression of Change scale 21 
MCID   Minimal Clinically Important Difference 22 
NPI   Neuropsychiatric Inventory 23 
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NPI-TBI-IA Rasch Neuropsychiatric Inventory Irritability/Aggression Scale for Traumatic 24 
 Brain Injury 25 
RCID  Robust Clinically Important Difference 26 
TBI  Traumatic brain injury 27 
 28 
  29 
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The Minimal Clinically Important Difference for the Rasch Neuropsychiatric Inventory 30 
Irritability and Aggression Scale for Traumatic Brain Injury 31 
The Minimal Clinically Important Difference (MCID) is the smallest change on a clinical 32 
measure that is associated with a meaningful perceived difference in an individual’s condition, 33 
function, or quality of life.  Meaningful change may be evaluated from the perspective of the 34 
person served, that of a close other, or a clinician involved in their care.   35 
A number of values for the MCID based on distribution-based statistical methods 36 
(i.e.,methods that compare change scores to a measure of variability)1 have been proposed 37 
including the standard error of measurement (SEM), standard deviation, reliable change index 38 
(RCI) and derivatives of these values.2  For example, 1.96SEM describes the 95% confidence 39 
interval for the SEM and the 95% confidence interval for the RCI is equal to 2.77SEM.3   40 
Anchored methods (i.e., those that compare change scores to change in another measure 41 
considered to be an external criterion)1 in which a hypothetical MCID value is evaluated in 42 
relationship to another measure that reflects meaningful change have also been recommended.1,4  43 
A Global Impression of Change (GIC) scale has been frequently used as the anchor for MCID 44 
estimates.  Current recommendations are to use both statistical and anchored methods to 45 
triangulate on the best supported value of the MCID.3,5  46 
In this paper, we estimate— from multiple perspectives using both statistical and 47 
anchored methods—the value of the MCID for a measure based on the Neuropsychiatric 48 
Inventory (NPI) subscales for irritability and aggression among individuals with traumatic brain 49 
injury (TBI).  The NPI was originally designed for administration as a structured interview for 50 
assessing neuropsychiatric syndromes with scoring based on the most problematic item on each 51 
subscale.6 We have developed a measure, the Rasch Neuropsychiatric Inventory Irritability and 52 
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Aggression Scale for TBI (NPI-TBI-IA), for use with individuals with TBI that combines the 53 
Irritability/Lability and Agitation/Aggression subscales and is based on scoring all specific items 54 
in these subscales.  The development and structural validation of this measureis described in 55 
detail in a prior publication.7 56 
Method 57 
Participants 58 
 Distribution-based indicators were derived from de-identified archival data obtained at 59 
baseline assessment in three studies of pharmacologic interventions for irritability and aggression 60 
after TBI conducted in rehabilitation outpatient settings in the United States: (1) single site 61 
amantadine trial,8 (2) amantadine multi-site intervention study (AIMS),9 and (3) a carbamazepine 62 
trial.10  These data were used in the development of the NPI-IA-TBI in English.7 Observer 63 
ratings included a sample of the 274 cases used in the final Rasch calibration of the NPI-TBI-IA 64 
(mean age=38.78 yrs; SD=13.09; 41% women).  Participant self-ratings included the 232 cases 65 
used in the final Rasch calibration of these data (mean age=39.12; SD=12.65; 38% women).  For 66 
anchor-based estimates, change scores from baseline to Day-28 and Day-60 follow-up were 67 
computed from de-identified data for the NPI-TBI-IA for 161 cases from the AIMS trial (mean 68 
age= 39.42; SD=12.56; 22% women).  These change scores were compared or “anchored” to 69 
Global Impression of Change scores provided by the participant, an observer, and a physician.  70 
Participants in all studies had a history of moderate-severe TBI and were at least 6 months post-71 
injury.  Additional details regarding these studies are available in prior reports.7-10  Analyses of 72 
the de-identified data sets used in this study was approved as exempt by the Indiana University 73 
IRB. 74 
 75 
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Measures 76 
 Rasch NPI TBI Irritability/Aggression Scale (NPI-TBI-IA).  The psychometric 77 
qualities of this measure were found acceptable in its initial development and evaluation.7  Using 78 
tables provided as supplemental material in that report, raw scores were converted to a Rasch 79 
metric on a 0-100 scale. 80 
 Global Impression of Change scale (GIC).  As part of the AIMS trial, GIC were 81 
independently completed by participants with TBI, an observer, and the physician conducting 82 
evaluations at 28-day and 60-day follow-ups.  Overall change in irritability and aggression was 83 
rated on a 7-point scale: (1) very much improved, (2) much improved, (3) minimally improved, 84 
(4) no change, (5) minimally worse, (6) much worse, and (7) very much worse.   85 
Statistical analyses 86 
 Observer and participant ratings on the NPI-TBI-IA were converted to a Rasch 0-100 87 
metric.  Distribution-based indicators were computed from baseline values.  The mean for 88 
observer baseline ratings=45.17 (SD=6.96) with no extreme scores; mean baseline participant 89 
ratings=40.68 (SD=10.56) with 8 zero scores and no maximum scores.   The Rasch person 90 
reliability coefficient of .89 for observer ratings and .85 for participant self-ratings were used to 91 
compute SEMs.  The reliability coefficient that is required in the computation of the SEM is the 92 
proportion of a measure that represents true variance; the Rasch person reliability coefficient 93 
provides a conservative estimate of this value.11  Missing item data were rare (<1%), and 94 
consequently imputation of missing values was not attempted. 95 
In anchored comparisons, change scores were computed by subtracting 28-day and 60-96 
day Rasch metric values from baseline values.  Specified cut-points (1 SEM, ½ SD, 1.96 SEM, 97 
2.77 SEM or RCI,  and 1 SD), representing hypothetical MCID, were selected as  distribution-98 
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based benchmarks. For ease of use and to avoid exaggerating the precision of this measure, cut-99 
points were rounded to the nearest ½ point.  The sample was then divided into those whose 100 
change scores indicated improvement greater or less than the selected cut-points. Finally, percent 101 
agreement between classification based on the selected cut-point and minimal to very much 102 
improvement on GIC completed by participants with TBI, an observer, and the physician were 103 
examined.  At Day 28, no participant or observer NP-TBI-IA scores were missing; 1 participant 104 
GIC and 3 physician GIC were missing.  At Day 60, 6 observer and 1 participant NPI-TBI-IA 105 
scores were missing; GIC data were also missing for these cases.  Because of the small number 106 
of missing data, imputation was not attempted.   107 
Results 108 
 Values for distribution-based indicators for both participant and observer ratings are 109 
reported in the far left column of Table 1.  In order to anchor these indicators to improvement on 110 
the GIC, we computed the ratio of cases in which NPI-TBI-IA scores at 28- and 60-day follow-111 
up reflect a positive change from baseline greater than or equal to the amount of change specified 112 
by each distribution-based indicator to the total number of cases with minimal to very much 113 
improvement on the GIC. 114 
Examination of Table 1 reveals that the percent of individuals achieving either a SEM or 115 
½ SD level of improvement on the NPI-TBI-IA with at least a minimal level of improvement 116 
recorded on the GIC is substantial (69-83%), suggesting that either of these levels might serve as 117 
the MCID.  Table 2 describes agreement between GIC and NPI-TBI-IA change scores at 60-day 118 
evaluations in greater detail at the ½ SD and 1 SD level of improvement.  There is only slight 119 
shift toward greater endorsement of “much” and “very much” general improvement at the 1 SD 120 
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improvement level.  A similar slight shift toward the perception of greater improvement was also 121 
apparent at 28-day evaluations (see Supplemental Table 1). 122 
Discussion 123 
Anchoring potential statistically-based MCID values to GIC ratings suggests that either 124 
the SEM or ½ SD level of improvement is considered by a large majority of participants, 125 
observers, or supervising physicians to represent meaningful improvement on the GIC. Since the 126 
SEM is the smallest amount of change that is statistically reliable, we suggest adopting the 127 
slightly more conservative value of ½ SD improvement as the MCID (3.5 for observer ratings;  128 
5.5 for participant self-ratings).  As would be expected, the percentage of cases with a positive 129 
GIC rating increases as the value of the required improvement on the NPI-TBI-IA increases.  130 
However, except for physician ratings at Day 28, the difference between percent agreement 131 
based at ½ SD level of improvement is not dramatically different from percent agreement based 132 
on 2.77 SEM (RCI) or 1 SD (see Table 1), reinforcing the ½ SD level as a reasonable value for 133 
the MCID.  The level of improvement indicated by the RCI or 1 SD might be considered what 134 
we have previously termed a “robust clinically important difference” (RCID).12  Because it is the 135 
traditional value for a large effect size, the 1 SD improvement is proposed as the RCID for the 136 
NPI-TBI-IA (7.0 for observer ratings; 10.5 for participant self-ratings).  On the other hand, the 137 
perception of greater improvement on the GIC at the 1 SD level compared to the ½ SD level is 138 
not marked.  For the NPI-TBI-IA, once the MCID threshold of ½ SD is crossed, further 139 
improvement is not strongly associated the perception of overall improvement.  140 
Limitations.  These analyses were based on retrospective data and may not be 141 
generalizable to all individuals with TBI. 142 
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Conclusions.  The MCID for the NPI-TBI-IA is represented by a ½ SD improvement for 143 
both participant and observer ratings; a 1 SD change represents a robust clinically important 144 
difference (RCID). 145 
 146 
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Table 1.  Percent with improvement on GIC showing positive change at or above 
distribution-based indicators for 28- and 60-day NPI-TBI-IA ratings  
Distribution-based 
indicators (rounded 
cut point) 
Participant Observer Physician 
 28-day 60-day 28-day 60-day 28-day 60-day 
Observer ratings 
1 SEM=2.31 (2.5) 68% 70% 72% 79% 71% 77% 
½ SD=3.48 (3.5) 69% 71% 74% 80% 73% 77% 
1.96SEM=4.53 (4.5) 70% 74% 77% 82% 76% 79% 
2.77SEM=6.40 (6.5) 76% 76% 78% 87% 80% 82% 
1 SD=6.96 (7.0) 78% 76% 80% 87% 83% 82% 
Participant self- ratings 
1 SEM=4.09 (4.0) 72% 76% 76% 80% 75% 78% 
½ SD=5.28 (5.5) 77% 80% 77% 83% 75% 81% 
1.96SEM=8.02 (8.0) 81% 84% 80% 87% 82% 84% 
2.77SEM=11.33 (11.5) 89% 83% 86% 88% 96% 86% 
1 SD=10.56 (10.5) 88% 82% 84% 87% 94% 87% 
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Table 2.  Percent indicating various levels of change on GIC with ½ SD or greater and 1 SD 
or greater change on 60-day NPI-TBI-IA ratings  
NPI-TBI-IA change 
score: 
Participant Observer Physician 
½ SD 1 SD ½ SD 1 SD ½ SD 1 SD 
Observer GIC ratings 
Very much improved 9% 11% 19% 21% 15% 16% 
Much improved 38% 41% 35% 39% 37% 37% 
Minimally improved 24% 24% 26% 27% 25% 29% 
No change 24% 21% 18% 13% 22% 18% 
Minimally worse 2% 2% 1% 0% 1% 0% 
Much worse 2% 1% 1% 0% 0% 0% 
Very much worse 1% 0% 0% 0% 0% 0% 
Participant GIC self- ratings 
Very much improved 10% 12% 21% 26% 16% 21% 
Much improved 39% 43% 32% 31% 38% 45% 
Minimally improved 31% 27% 30% 30% 27% 21% 
No change 18% 18% 16% 13% 19% 13% 
Minimally worse 1% 0% 0% 0% 0% 0% 
Much worse 1% 0% 1% 0% 0% 0% 
Very much worse 0% 0% 0% 0% 0% 0% 
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Highlights 
• A measure combining the Irritability/Lability and Agitation/Aggression subscales of the 
Neuropsychiatric Inventory (NPI-TBI-IA) has been developed for use with individuals with 
traumatic brain injury (TBI). 
• The new measure (the Rasch Neuropsychiatric Inventory Irritability and Aggression Scale 
for TBI; NPI-TBI-IA) was developed with Rasch analysis and includes responses to all 
specific items on these subscales. 
• The Minimal Clinically Important Difference (MCID) is the smallest change on a clinical 
measure that is associated with a meaningful perceived difference in an individual’s 
condition, function, or quality of life.   
• We determined the MCID for this measure using distribution-based and by anchoring the 
measure to Global Impression of Change scales completed by individuals with TBI, their 
observers, and their physicians. 
• Our analysis suggests that the MCID for the NPI-TBI-IA is ½ standard deviation and that a 
standard deviation change indicates a Robust Clinically Important Difference for both 
observer ratings and participant self-ratings. 
